ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ENTA vs BNTC // EV/EBITDA & P/E VALUATION

Enanta Pharmaceuticals Inc. (NASDAQ) VS. Benitec Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: ENTA 2 — BNTC 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTA VS. BNTC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ENTA BNTC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -9.91% -7.66% -2.25 BNTC /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -3.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ENTA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.6 42.6 -5.92 BNTC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $324.7M $308.1M $16.7M ENTA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ENTA REV BNTC REV ENTA GROSS % BNTC GROSS % ENTA FCF BNTC FCF
FY 2025 $65.3M $0 — — -$32.2M -$23.6M
FY 2024 $67.6M $0 — — -$96.7M -$19.6M
FY 2023 $79.2M $0 — — -$103.2M -$18.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTA // BETA —
BNTC // BETA —